Companion diagnostics have had a profound impact on the way in which cancer is treated – and the promise of truly personalised medicine is edging closer towards reality.
The pace of change is accelerating and while it brings many new opportunities, the ever-increasing complexity also creates multiple challenges – for physicians as well as drug manufacturers.
In this latest paper from the Ipsos Oncology Centre of Excellence, Pieter De Richter – Head of Ipsos’ Molecular Diagnostics (MDx) Portfolio – draws on current data from our Oncology MDx Monitor to show how this complexity can be harnessed to achieve success for all stakeholders, including the patient.
Exploring the use of the Friends and Family Test in General Practice
Ipsos were commissioned by the Policy Innovation Research Unit (PIRU) based at the London School of Hygiene and Tropical Medicine to conduct qualitative case study interviews with GP practices about their experience of using the Friends and Family Test (FFT).